Nektar Therapeutics

Nektar Therapeutics develops medicines for immunotherapy globally. Theyre developing rezpegaldesleukin for lupus erythematosus and ulcerative colitis, and atopic dermatitis and psoriasis. Rezpegaldesleukin is in phase 2 clinical trials. NKTR-255 is an IL-15 receptor agonist in phase 1 clinical trial to treat cancer. The company has collaborations with several major pharmaceutical companies. Nektar was incorporated in 1990 and is headquartered in San Francisco, California.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

59.6 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0

Nektar Therapeutics

Overview

Strengths

Weaknesses

Key Financial Data